This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider.
Jeffrey J. Swigris, DO: Welcome to Medscape InDiscussion on the topic of idiopathic pulmonary fibrosis, or IPF. I'm Dr Jeff Swigris, and today in our final first-season episode, we'll be discussing what the future of medical care for patients with IPF will look like in terms of prevention, earlier detection of disease, and the diagnostic tests and therapies that will make it all possible. We've invited a person whose impressive portfolio of clinical and translational research includes among other things, studies of novel compounds for IPF and other interstitial lung diseases (ILDs). He is director of the Interstitial Lung Disease Program at the University of Southern California in Los Angeles, and professor of interstitial lung disease at Imperial College London. Toby Maher, welcome, and thank you for making the time for this conversation.
Toby M. Maher, MD, PhD: Jeff, thank you. It's always a pleasure to be catching up, especially when other people can listen.
Swigris:Toby, let's talk first about how you became interested in the field of ILD. What was the initial thing that piqued your interest in this field?
